MedtronicHQ

Medtronic, an Ireland-based medical technology company, has launched a new version of its superDimension lung navigation system software.

The system provides a minimally invasive approach to access difficult-to-reach areas of the lung, allowing the diagnosis of lung diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

By using the patient’s CT scan, superDimension planning software generates a 3D virtual bronchial tree, which helps physicians to map pathways to reach pulmonary targets during the electromagnetic navigation bronchoscopy (ENB) procedure.

The virtual roadmap allows physicians to navigate and steer a catheter to the target quickly and accurately.

Once the target tissue is reached, physicians pass the new superDimension triple needle cytology brush through an endoscopic catheter to secure tissue samples from endobronchial lesions, peripheral lung nodules, or lung masses.

"Improving chances to more easily identify patients at an early stage may bring a dramatic change in the societal impact of lung cancer."

Medtronic Early Technologies EMEA vice-president Bronwyn Brophy said: "This minimally invasive device helps physicians prepare for the most appropriate therapy depending on the stage of the cancer.

"Improving chances to more easily identify patients at an early stage may bring a dramatic change in the societal impact of lung cancer."

The company recently started a 2,500 patient, international study to evaluate the real-world impact of its superDimension navigation system.

The study is designed to support and validate the superDimension system, which the company hopes will become the global standard of care for obtaining lung tissue biopsies from the periphery of the lungs.

Medtronic Early Technologies president Chuck Brynelsen said: "These advanced tools and technologies demonstrate Medtronic’s commitment to expanding the specialised lung health products available to pulmonologists and thoracic surgeons.

"The continuum of care is the healthcare journey a patient takes from diagnosis to recovery. Our goal, across this continuum, is to diagnose earlier, intervene earlier, treat better and help patients recover faster."

In September, Medtronic acquired US-based medical device firm Lazarus Effect for $100m. Based in Campbell, California, Lazarus Effect is involved in developing acute ischemic stroke products, which facilitate the capture and removal of clots.

Image: Medtronic world headquarters in Fridley, Minnesota, US. Photo: courtesy of Bobak Ha’Eri.